Sign In
27 Feb 2025 12:35
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
27 February 2025
EDX Medical Group plc
AQSE: EDX
("EDX Medical" or the "Group" or "Company")
DIRECTOR DEALING
CAMBRIDGE, UK: EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, cardiovascular and infectious diseases, today announces that Professor Sir Christopher Evans OBE, founder, director and Chief Scientific Officer of the Company, purchased 30,000 ordinary shares in the Company on February 26, 2025, at a price per share of 13.49 pence.
Following this purchase, Professor Evans owns 130,680,000 ordinary shares, representing 37.33% of the issued share capital.
The directors of the Company accept responsibility for the contents of this announcement.
ENDS
Contacts
EDX Medical Group Plc | |
Dr Mike Hudson (Chief Executive Officer) | +44 (0)7812 345 301 |
Oberon Capital | |
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) | +44 (0)20 3179 5300 |
IFC Advisory (Investor Relations) | |
Tim Metcalfe | +44 (0)20 3934 6630 |
Graham Herring | |
Media House International | |
Ramsay Smith
Gary McQueen | +44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
Notes for Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has a number of significant strategic partnerships including; a product technology collaboration with Thermo Fisher EMEA Ltd, a logistics partnership with Fedex and a distribution agreement with Caris Life Sciences inc, each world leaders in their respective fields.
www.edxmedical.com
Follow the stocks
